Abstract
Objective: Alectinib hydrochloride (AH), a poorly soluble drug, exhibits low solubility thereby very low bioavailability. The present study aims to develop and optimize surface-modified solid dispersion of AH (AH-SMSD) with enhanced solubility and dissolution using Soluplus® (SOL) and Gelucire 44/14 (GEL) as a polymer and surfactant, respectively.
Methods: Design of Experiments (DoE) was implemented to optimize the weight ratio of SOL (X1), and GEL (X2), keeping the drug weight constant to maximize the solubility (Y1) and dissolution (Y2). The optimized solid dispersion was subjected to solubility and dissolution in bio-relevant media and characterized using differential scanning calorimetry (DSC), Powder X-ray diffraction (pXRD), Fourier-transform infrared (FTIR), and scanning electron microscopy (SEM).
Results: A statistically significant model is obtained for solubility and dissolution through DoE. Formulation (F9) containing AH: SOL: GEL in weight ratios 1:5:5 showed a 547-fold increase in solubility. This solubility enhancement further translated into dissolution improvement with drug release of >80% in 15 min. The optimized formulation also showed improved solubility and dissolution in fasted-state bio-relevant media. DSC and pXRD showed a change in the crystallinity pattern of the drug. FTIR showed the existence of weak intermolecular interactions. Morphological evaluation through SEM demonstrated that the drug particles were dispersed to a hydrophilic carrier matrix, thus, transforming the hydrophobic drug into a hydrophilic form.
Conclusion: AH-SMSD with enhanced solubility and dissolution was successfully developed. The optimized formulation also showed improvement in the bio-relevant media and therefore has the potential to improve in vivo oral bioavailability (however, needs to be experimentally explored).
Publisher
Innovare Academic Sciences Pvt Ltd
Reference50 articles.
1. Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G. FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib. Clin Cancer Res. 2016 Nov 1;22(21):5171-6. doi: 10.1158/1078-0432.CCR-16-1293, PMID 27413075.
2. Morcos PN, Parrott N, Banken L, Timpe C, Lindenberg M, Guerini E. Effect of the wetting agent sodium lauryl sulfate on the pharmacokinetics of alectinib: results from a bioequivalence study in healthy subjects. Clin Pharmacol Drug Dev. 2017 May 1;6(3):266-79. doi: 10.1002/cpdd.299, PMID 27545871.
3. Morcos PN, Yu L, Bogman K, Sato M, Katsuki H, Kawashima K. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiotica. 2017 Mar;47(3):217-29. doi: 10.1080/00498254.2016.1179821, PMID 27180975.
4. Parrott NJ, Yu LJ, Takano R, Nakamura M, Morcos PN. Physiologically based absorption modeling to explore the impact of food and gastric pH changes on the pharmacokinetics of alectinib. AAPS J. 2016 Nov 1;18(6):1464-74. doi: 10.1208/s12248-016-9957-3, PMID 27450228.
5. Australian public assessment reports (AusPAR). Woden: Therapeutic Goods Administration. Extract from the Clinical Evaluation Report for Alectinib; 26 Dec 2017. Available from: https://www.tga.gov.au/resources/auspar/auspar-alectinib-hydrochloride. [Last accessed on 18 Apr 2023]
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献